Study data published in The Lancet suggest that that a triple antiviral therapy, interferon beta 1b, lopinavir-ritonavir and ribavirin, may be safe and effective in treating patients with mild to moderate cases of COVID-19, reported ABC News.
Researchers assigned over 120 patients with mild to moderate COVID-19 symptoms to a cocktail of all three drugs and gave the other group only lopinavir-ritonavir.
The typical patient given the three drug-combination tested negative for the virus five days earlier than those who received just a single drug.
Additionally, the triple therapy treatment group had a shorter hospital stay and reported that their symptoms disappeared much faster than the control group.
The main side effects of the medications were nausea and diarrhoea, but there was no difference between the two groups, and none of the patients died.